Related references
Note: Only part of the references are listed.Action mechanisms of Onabotulinum toxin-A: hints for selection of eligible patients
Carlo Lovati et al.
NEUROLOGICAL SCIENCES (2017)
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
Amy R. Tso et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2017)
Migraine Triggers and Oxidative Stress: A Narrative Review and Synthesis
Jonathan M. Borkum
HEADACHE (2016)
Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
XiChun Zhang et al.
CEPHALALGIA (2016)
Migraine features in migraineurs with and without anxiety-depression symptoms: A hospital-based study
Filippo Baldacci et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2015)
CGRP Mechanism Antagonists and Migraine Management
Nazia Karsan et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2015)
Evidences of Reduced Antioxidant Activity in Patients With Chronic Migraine and Medication-Overuse Headache
Cinzia Lucchesi et al.
HEADACHE (2015)
Analysis of body mass index, psychiatric comorbidity, sleep-wake pattern and occurrence of fatigue in episodic and chronic migraine patients
Cinzia Lucchesi et al.
JOURNAL OF HEADACHE AND PAIN (2015)
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Mohammad H. Forouzanfar et al.
LANCET (2015)
OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine
Eva Cernuda-Morollon et al.
PAIN (2015)
Protective effect of botulinum toxin A after cutaneous ischemia-reperfusion injury
Akihiko Uchiyama et al.
SCIENTIFIC REPORTS (2015)
Refractory chronic migraine: a Consensus Statement on clinical definition from the European Headache Federation
Paolo Martelletti et al.
JOURNAL OF HEADACHE AND PAIN (2014)
SYSTEMS ANALYSIS OF TRANSCRIPTIONAL DATA PROVIDES INSIGHTS INTO MUSCLE'S BIOLOGICAL RESPONSE TO BOTULINUM TOXIN
Kavitha Mukund et al.
MUSCLE & NERVE (2014)
The International Classification of Headache Disorders, 3rd edition (beta version)
Andre Bes et al.
CEPHALALGIA (2013)
Triggers in Allodynic and Non-Allodynic Migraineurs. A Clinic Setting Study
Filippo Baldacci et al.
HEADACHE (2013)
Beyond Neurovascular: Migraine as a Dysfunctional Neurolimbic Pain Network
Morris Maizels et al.
HEADACHE (2012)
BEHAVIORAL AND IMMUNOHISTOCHEMICAL EVIDENCE FOR CENTRAL ANTINOCICEPTIVE ACTIVITY OF BOTULINUM TOXIN A
I. Matak et al.
NEUROSCIENCE (2011)
Thalamic Sensitization Transforms Localized Pain into Widespread Allodynia
Rami Burstein et al.
ANNALS OF NEUROLOGY (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
S. K. Aurora et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers
D. C. Buse et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
Conceptualizing the relationship between chronic migraine and episodic migraine
Richard B. Lipton et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2009)
Cutaneous allodynia in the migraine population
Richard B. Lipton et al.
ANNALS OF NEUROLOGY (2008)
Clinical course in migraine: Conceptualizing migraine transformation
Marcelo E. Bigal et al.
NEUROLOGY (2008)
TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons
Helen E. Gibson et al.
NEURON (2008)
Relationship between biofeedback and oxidative stress in patients with chronic migraine
I. Ciancarelli et al.
CEPHALALGIA (2007)